TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: 30 days-mortality
Endpoint domain: Mortality/survival
Primary endpoint: clinically significant abnormal findings in physical examination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success Rate of Primary Prostate Cell Culture
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: EEG pattern
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Reduced levels of Homocysteine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: changes in GLP-1 production
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Self-care of heart failure index
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of Subjects With Manifest Refraction Cylinder ≤ 0.50 D
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Best Corrected Distance Visual Acuity (BCDVA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Balance problems detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of women with an appropriate rise in Hemagglutination Inhibition (HI) titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of infants with HI titers greater than or equal to 40 in cord blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of solicited and unsolicited adverse events post-vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Airway inflammation evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Forced Expiratory Volume in One Second (FEV1) AUC 0-24
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Changes from baseline in pulse pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) of Venetoclax in Combination with Obinutuzumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biological effects of lenvatinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percent Confidence in Assessment of Left Atrial Appendage Thrombus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Area Under the Concentration-time Curve of the BI 730357 in Plasma (AUC0-tz)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Measured Concentration of the BI 730357 in Plasma (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of non-progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Plasma concentrations of C-reactive protein (CRP) and cytokines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Days to Lesion Resolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients with surgical site infection
Endpoint domain: Adverse events/effects
Primary endpoint: Objective response by RECIST criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Vocal Loudness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: A1C (%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Exhaled breath pattern
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to First Occurrence of Major Adverse Cardiovascular Events (MACE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: intestinal motility at diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Hematology value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: 18F-choline uptake as a marker of plaque inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sensitivity of 18F-choline PET
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: specificity of 18F-choline PET
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: negative predictive value of 18F-choline PET
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-72 - Area Under the Concentration Time Curve From Time Zero to Time 72 Hours (Per Participant)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of return ED visits
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage of Subjects Rating Each Device as Easy/Very Easy to Use
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Symptoms and medication scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Microbial Community Richness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Microbial Community Evenness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: morbidity and complication rates
Endpoint domain: Adverse events/effects
Primary endpoint: Mean Turesky Plaque Index (TPI) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Global response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: change in function
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change of Harvey Bradshaw Activity Index (HBI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change of partial Mayo Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Changes in liver steatosis score according to ultrasonography
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Anti-hepatitis B vaccine antibody response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Sustained Viral Response (SVR12)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Identification of triple signal in the common carotid artery wall
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Safety as assessed by the collection of adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Antiviral activity as assessed by HCV RNA viral load
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients who performed EGFR mutation test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Venous Thromboembolic (VTE) Events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Major Bleeding Events (MBE)
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of patients with pancreatic cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Proportion of resected lesions with invasive malignancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Sickle Cell Self-efficacy Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of Participants Vaccinated With PR5I With Acceptable Antibody Response to Haemophilus Influenzae Type b, Diphtheria, Tetanus, and Poliovirus Types 1, 2 & 3, at 5 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants Vaccinated With PR5I With Acceptable Ab Response or Seroresponse Rates to All Antigens Contained in the PR5I Vaccine One Month After the Toddler Dose at 13 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants Vaccinated With PR5I Compared With INFANRIX™ Hexa With Acceptable Ab Response to Haemophilus Influenzae Type b, Diphtheria, Tetanus, and Poliovirus Types 1, 2 & 3, at 5 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Pneumococcal serotype specific geometric mean concentrations (GMCs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Complete or partial intracranial response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Depth of Anesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With a Menstrual Blood Loss (MBL) Volume of < 80 mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With a ≥ 50% Reduction in MBL Volume From Baseline to the Final Month
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oxygen status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Evaluation of neonatal intensive care stay
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Differences in serum protein profiles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Differences in the number of peptide matches
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Step Length During Gait
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Walking Speed During Gait
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of inpatient nights spent in hospital
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Number of study participants with depression, anxiety and stress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Nasal cavity diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NEWS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: High-sensitivity cardiac troponin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of MACE composite criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: early detection of joint abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Mean arterial pressure variation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Functional ability test Handgrip
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional ability test 2-minute walk
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in isokinetic work (W30)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in total PPG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: recurrence of candida infections
Endpoint domain: Adverse events/effects
Primary endpoint: Physician adherence to the USPHS Guideline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient perception of physician
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Negligible pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Satisfactory healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: No bleeding and infection of the perineum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Reduction in Pediatric Anxiety Rating Scale (PARS) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Peak Glucagon Response to Hypoglycemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Luteinizing hormone rise
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Positive and Negative Syndrome Scale - Excited Component
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brachial blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Success on patient global assessment of pain control
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Level of Anti-Rubella Antibody
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: change in TRAb level (IU/L)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Frequency of subjects with HbA1c levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time to progression (TTP) of disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of Range of motion of hip flexion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of Fingertip to floor distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Compliance to the exercise programme
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Difference in component of microbiota
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Immune cell proportions in tumor samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Immune cell proportions in peripheral blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Acceptability of de-implementation strategies
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Hand Movements Required
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Recommended Phase 2 Dose (RP2D)
Endpoint domain: Adverse events/effects
Endpoint subdomain: Any subdomain
Primary endpoint: Relapse of stone disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Visual Analog Scale (High rating)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Modified Progression-free survival (mPFS)
Endpoint domain: Mortality/survival
Primary endpoint: Prostate Cancer (PC)-related Mortality (PM)
Endpoint domain: Mortality/survival
Primary endpoint: Completion of one quitline counseling session
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Maximum decrease in cardiac output
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Average daily enteral caloric intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Presence of anti-ficolin-3 antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Time to first demyelinating event
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: continuous abstinence from smoking
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Behavioral Activation for Depression Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Probability of therapeutic target attainment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of agreement between ultrasound interpretations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUSCAN NR3.1 Pain Subdomain Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with procedure-related or device-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Child and Adolescent Trauma Screen (CATS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Toxicokinetics of bisphenol-S
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of Serious adverse experiences (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence, intensity and relationship to vaccination of solicited local and general symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence, intensity and causal relationship of unsolicited adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: knowledge of contraceptive methods
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Median Change From Baseline to Week 7 of Interferon Inducible Factors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Tumor Infiltrating Lymphocytes (TILs) as Measured by Percent Positive CD8 and Positive CD4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Fat tissue biopsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effect size of HD-tDCS for anomia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mean Change From Baseline to Day 84 for IRLSSG Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of samples with identifiable Notch, Wnt and Hedghog pathways
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 90 days mortality from ICU admission
Endpoint domain: Mortality/survival
Primary endpoint: logVA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: logCS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference from baseline in summary Index of EuroQol -5D
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Feedback from Respiratory Therapists on Extubation Advisor TM
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Feedback from Intensivists on Extubation Advisor TM Report
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Technical feasibility of real-time implementation of Extubation Advisor TM
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Echo Comet Score at day 1 post-delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: central subfield thickness in micrometer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: p1 amplitude of mfERG
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in cognitive tasks measures
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Use of Oral Prednisone for Acute Asthma Exacerbations
Endpoint domain: Adverse events/effects
Primary endpoint: 3 year Relapse Free Survival (RFS)
Endpoint domain: Mortality/survival
Primary endpoint: Number of safety events during administration of oral oncolytic medications
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of subjects feel comfortable to use ReX-C for pill intake and medication management
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Rate of adherence (number of pill intakes) during treatment with ReX-C
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Annualized Total Bleeding Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression of HIV-1 disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in overall physical function
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in overall pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnosis of major depression within 2 weeks of screening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment of major depression within 1 month of diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Transition of care from pregnancy to postpartum
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Thyromental distance (TMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Other airway measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mentalization level
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Serum Apelin Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Retention in timely monitoring of viral load
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the Macular Pigment Optical Density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perinatal Grief Scale (change)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Inventory of Complicated Grief (change)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Beck Depression Inventory-II (change)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Edinburgh Postnatal Depression Scale (change)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: State and Trait Anxiety Inventory form Y (change)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Positive and Negative Affect Scale (change)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of patients abstinent from alcohol
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Consent and follow-up rates
Endpoint domain: Resource use
Endpoint subdomain: Other resource use